Preston Klassen - Aug 10, 2023 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President & Head of R & D, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
4
Date filed
8/14/2023, 04:24 PM
Previous filing
Jun 12, 2023
Next filing
Jan 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +225K $0.00 225K Aug 10, 2023 Common Stock 225K $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.